Ads
related to: advanced ovarian cancer treatment guidelines nccn- Oral Medication
Learn More About An Oral Treatment
Option For Ovarian Cancer.
- Side Effect Information
Learn More About Potential Side
Effects And Safety Information.
- Genomic Testing
Read How Testing Could
Help Inform Your Treatment Plan.
- Clinical Study Data
Find Clinical Study Data
At The Patient Site.
- Oral Medication
Search results
Results From The WOW.Com Content Network
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A " maintenance regimen " refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow.
The Journal of the National Comprehensive Cancer Network, established in 2003, is a monthly peer-reviewed medical journal of oncology and the official journal of the National Comprehensive Cancer Network (NCCN). It is published by Harborside Press and the editor-in-chief is Margaret Tempero (UCSF Helen Diller Family Comprehensive Cancer Center ...
(Reuters) -The U.S. Food and Drug Administration said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for patients with a type of ovarian cancer.
The National Comprehensive Cancer Network (NCCN) is an alliance of 33 [1] cancer centers in the United States, most of which are designated by the National Cancer Institute (one of the U.S. National Institutes of Health) as comprehensive cancer centers. It is a non-profit organization with offices in Plymouth Meeting, Pennsylvania.
As ovarian cancer is rarely symptomatic until an advanced stage, [42] regular pre-emptive screening is a particularly important tool for avoiding the late stage at which most patients present. However, A 2011 US study found that transvaginal ultrasound and cancer marker CA125 screening did not reduce ovarian cancer mortality. [ 43 ]
Ads
related to: advanced ovarian cancer treatment guidelines nccn